Goal to make accessible child-friendly treatment for Schistosomiasis

UTRECHT, Netherlands-   UK-based Schistosomiasis Control Initiative (SCI), part of Imperial College London, is reinforcing the international non-profit Pediatric Praziquantel Consortium. The aim of the Consortium is to develop, register and make available a new child-friendly praziquantel formulation for the more than 25 million preschool-age children suffering from schistosomiasis, a parasitic disease endemic in most of Sub-Saharan Africa. This age group currently lacks a suitable treatment.

SCI, with their extensive expertise in working with Ministries of Health across sub-Saharan Africa for the control and potential elimination of schistosomiasis, will support the Consortium in preparing and implementing the Access and Delivery plan of the new pediatric formulation in endemic countries. Dr Elly Kourany Lefoll, Program Lead of the pediatric praziquantel development program and Head of Drug Development Neglected Tropical Diseases (NTDs) at Merck KGaA, Darmstadt, Germany, comments: “We are very pleased that SCI joins our Consortium. Over the last four years, we’ve made important progresses across the pediatric praziquantel development program, with a phase II clinical trial currently being conducted in Ivory Coast. This means that we are now testing the new formulation in schistosome-infected pre-school age children to identify the optimal dose.”

High morbidity rates

If not treated properly, schistosomiasis results in high morbidity, including anemia, stunted growth and reduced learning ability. In some cases, the disease can even be fatal. “As we are advancing in our development program,” Dr Kourany-Lefoll continues, “we have started to develop a plan to make the child- friendly praziquantel formulation accessible to children under six years of age in endemic countries. We are reaching out to access experts, and other key stakeholders, such as the World Health Organization (WHO) and governmental representatives from Sub-Saharan African countries to gain their input and support. SCI will play a crucial role in this endeavor.”

For SCI this partnership opens up different opportunities. SCI’s goal is to reduce the global disease burden of NTDs, including schistosomiasis, in sub-Saharan Africa by 2030 in accordance with the United Nations Sustainable Development Goals. Professor Fenwick, SCI’s founder and director, says, “We have been in contact with the Consortium for many years, and we look forward to this collaboration. We see the pediatric praziquantel formulation as a breakthrough in the battle against schistosomiasis in infected young children, a group lacking suitable treatment until now.” He adds, “Apart from creating awareness, changing perceptions and fostering global support for NTD Programmes, at SCI, we also put great emphasis on ensuring universal access to effective treatment for everyone who suffers from NTDs.”

Therapeutic tools

The know-how of SCI in deploying preventative and therapeutic tools and strategies to eliminate NTDs complements the existing scientific and regulatory expertise provided by the other six partners of the Consortium. Moreover, SCI has a broad network among policy makers such as the WHO, Ministries of Health, academic institutions, funders and other stakeholders which are key players in the implementation of an effective awareness and sensitization campaign in the coming years.

Schistosomiasis (also known as bilharzia) is one of the most prevalent parasitic diseases in Africa and a very important one in terms of public health burden and economic impact. It is a poverty-related disease that leads to chronic illness. The threat posed by schistosomiasis is substantial, with 78 affected countries, 700 million people at risk and an estimated 258 million people infected. More than 90% of patients live in Africa, where the disease affects a large proportion of children under the age of 14.

About the Pediatric Praziquantel Consortium

The Pediatric Praziquantel Consortium is an international not-for-profit partnership that aims to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children. Its mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in this age group. The pediatric formulation under investigation has been designed to be smaller, exhibit an improved palatability and be orally dispersible compared to the current commercial formulation.

The Consortium was established in July 2012 by Merck KGaA, Darmstadt, Germany (Merck KGaA), Astellas Pharma Inc. (Astellas), Swiss Tropical and Public Health Institute (Swiss TPH) and Lygature (formerly TI Pharma). At the beginning of 2014, Farmanguinhos and Simcyp, a Certara company, joined the Consortium as full partners. The Schistosomiasis Control Initiative (SCI), part of Imperial College London, joined in 2016.

Merck KGaA, Darmstadt, Germany leads the program and brings expertise and support related to praziquantel, including resources from different areas (drug product manufacturing, pre-clinical, clinical, regulatory) needed for clinical development and to efficiently execute the project. Astellas contributes by providing its innovative pharmaceutical technologies in the area of pediatric drug formulation development as well as clinical development in children. Swiss TPH brings extensive experience in helminths biological and pharmacological research, epidemiology and clinical research in endemic regions.

The governance is facilitated by Lygature, a Dutch non-profit organization and independent party with an extensive portfolio of international public-private partnerships in drug research and development, including in the area of neglected diseases. Farmanguinhos, the federal governmental pharmaceutical laboratory of the Fiocruz Foundation in Brazil, brings unique expertise to produce and distribute the new pediatric formulations product in endemic countries. Simcyp, a Certara company, brings expertise in pharmacokinetic modelling for better predicting the appropriate dosage for use in the pediatric clinical trials. SCI, part of Imperial College London, provides the necessary expertise to define and execute the access strategy and plan as well as to initiate and implement NTD control and elimination programs in Sub-Saharan Africa. – PRNewswire

Related Posts

Leave a Reply